Zuiverloon Tahlita C M, van Kessel Kim E M, Bivalacqua Trinity J, Boormans Joost L, Ecke Thorsten H, Grivas Petros D, Kiltie Anne E, Liedberg Fredrik, Necchi Andrea, van Rhijn Bas W, Roghmann Florian, Sanchez-Carbayo Marta, Schmitz-Dräger Bernd J, Wezel Felix, Kamat Ashish M
Department of Urology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands; University of Colorado Comprehensive Cancer Center, Aurora, CO.
Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.
Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar 2.
Several guidelines exist that address treatment of patients with nonmetastatic muscle-invasive bladder cancer (MIBC). However, most only briefly mention follow-up strategies for patients and hence the treating physician is often left to infer on what the preferred follow-up schema would be for an individual patient. Herein, we aim to synthesize recommendations for follow-up of patients with MIBC for easy reference.
A multidisciplinary MIBC expert panel from the International Bladder Cancer Network was assembled to critically assess currently available major guidelines on surveillance of MIBC patients. Recommendations for follow-up were extracted and critically evaluated. Important considerations for guideline assessment included both aspects of oncological and functional follow-up-frequency of visits, the use of different imaging modalities, the role of cytology and molecular markers, and the duration of follow-up.
An International Bladder Cancer Network expert consensus recommendation was constructed for the follow-up of patients with MIBC based on the currently available evidence-based data.
现有多项指南涉及非转移性肌层浸润性膀胱癌(MIBC)患者的治疗。然而,大多数指南仅简要提及患者的随访策略,因此治疗医师常常需要自行推断个体患者的首选随访方案。在此,我们旨在综合MIBC患者随访的建议以供便捷参考。
组建了一个来自国际膀胱癌网络的多学科MIBC专家小组,以严格评估目前可用的关于MIBC患者监测的主要指南。提取并严格评估随访建议。指南评估的重要考量因素包括肿瘤学和功能随访两个方面——就诊频率、不同成像方式的使用、细胞学和分子标志物的作用以及随访时长。
基于目前可得的循证数据,构建了一项关于MIBC患者随访的国际膀胱癌网络专家共识建议。